Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Vesigen’s ARMMs technology enables translation of new modalities such as RNAs and gene-editing complexes into novel treatments for multiple diseases .
Lead Product(s): ARMMs based cell and gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $28.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 22, 2020